Topics

Pfizer and Sangamo's haemophilia A gene therapy shows promise at Phase 1/2

06:01 EDT 8 Jul 2019 | Pharmafile

Pfizer and Sangamo Therapeutics have shared new Phase 1/2 data for their investigational SB-525 gene therapy in the treatment of haemophilia A, showing that it was “generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) activity levels.”

The shared data was drawn from research conducted in 10 participants and was presented at the 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH), in Melbourne, Australia.

read more

Original Article: Pfizer and Sangamo's haemophilia A gene therapy shows promise at Phase 1/2

NEXT ARTICLE

More From BioPortfolio on "Pfizer and Sangamo's haemophilia A gene therapy shows promise at Phase 1/2"

Quick Search

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...